

Perceptions of Treatments in AML – A Survey of 375 European Haematologists

This Infographic was developed and funded by Jazz Pharmaceuticals and is intended for European Healthcare Professionals only.


The 2022 AML treatment perceptions survey results

Around 375 haematologists and oncologists took part in a Jazz Pharmaceuticals commissioned survey to understand physicians' perceptions of AML treatments, particularly, the role of intensive chemotherapy for induction of remission in newly diagnosed AML.

Who took part in the survey?

75 Haematologists from each of the

5 European countries:
UK, France, Germany, Italy, Spain



What we found out

54%

of patients in the prior 6 months were eligible for

intensive chemotherapy

Most haematologists indicated that (≥91%):

1st

First treatment for newly diagnosed AML has the biggest impact on disease



Intensive chemotherapy should be the default induction for all eligible patients



The **highest intensity regimen** appropriate for the patient offers the **best chance of long-term overall survival**



Regimens with **curative intent** should **start with intensive chemotherapy induction**




Starting with intensive chemotherapy generally gives patients **more options for future treatments** compared to lower-intensity therapy



64

Average number of AML patients they'd seen in the last 6 months:

"Cure" was variably defined by physicians as a remission duration of:



In conclusion, for eligible patients with newly diagnosed AML, most physicians thought that **intensive chemotherapy gives the best chance of favourable outcomes**